Senzime AB (Sweden) Performance
| SEZI Stock | SEK 5.71 0.02 0.35% |
The entity has a beta of 0.32, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Senzime AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Senzime AB is expected to be smaller as well. At this point, Senzime AB has a negative expected return of -0.46%. Please make sure to validate Senzime AB's potential upside, kurtosis, and the relationship between the value at risk and skewness , to decide if Senzime AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Senzime AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 160.3 M | |
| Total Cashflows From Investing Activities | -3 M |
Senzime |
Senzime AB Relative Risk vs. Return Landscape
If you would invest 800.00 in Senzime AB on August 25, 2024 and sell it today you would lose (229.00) from holding Senzime AB or give up 28.62% of portfolio value over 90 days. Senzime AB is generating negative expected returns and assumes 3.2025% volatility on return distribution over the 90 days horizon. Simply put, 28% of stocks are less volatile than Senzime, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Senzime AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Senzime AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Senzime AB, and traders can use it to determine the average amount a Senzime AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1432
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SEZI |
Estimated Market Risk
| 3.2 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Senzime AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Senzime AB by adding Senzime AB to a well-diversified portfolio.
Senzime AB Fundamentals Growth
Senzime Stock prices reflect investors' perceptions of the future prospects and financial health of Senzime AB, and Senzime AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Senzime Stock performance.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 771.13 M | |||
| Shares Outstanding | 69.88 M | |||
| Price To Earning | (25.28) X | |||
| Price To Book | 2.70 X | |||
| Price To Sales | 60.95 X | |||
| Revenue | 10.98 M | |||
| EBITDA | (73.22 M) | |||
| Cash And Equivalents | 74.87 M | |||
| Cash Per Share | 0.42 X | |||
| Total Debt | 617 K | |||
| Book Value Per Share | 3.75 X | |||
| Cash Flow From Operations | (81.33 M) | |||
| Earnings Per Share | (1.37) X | |||
| Total Asset | 174.62 M | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
About Senzime AB Performance
Assessing Senzime AB's fundamental ratios provides investors with valuable insights into Senzime AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Senzime AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Senzime AB develops patient-oriented monitoring systems that assess patients biochemical and physiological processes before, during and after surgery in Sweden. Senzime AB was founded in 1997 and is based in Uppsala, Sweden. Senzime AB is traded on Stockholm Stock Exchange in Sweden.Things to note about Senzime AB performance evaluation
Checking the ongoing alerts about Senzime AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Senzime AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Senzime AB generated a negative expected return over the last 90 days | |
| Senzime AB has high historical volatility and very poor performance | |
| The company reported the revenue of 10.98 M. Net Loss for the year was (82.14 M) with loss before overhead, payroll, taxes, and interest of (4.39 M). | |
| Senzime AB has accumulated about 74.87 M in cash with (81.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42. | |
| Roughly 44.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Senzime AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Senzime AB's stock is overvalued or undervalued compared to its peers.
- Examining Senzime AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Senzime AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Senzime AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Senzime AB's stock. These opinions can provide insight into Senzime AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Senzime Stock Analysis
When running Senzime AB's price analysis, check to measure Senzime AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senzime AB is operating at the current time. Most of Senzime AB's value examination focuses on studying past and present price action to predict the probability of Senzime AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senzime AB's price. Additionally, you may evaluate how the addition of Senzime AB to your portfolios can decrease your overall portfolio volatility.